最新ニュース Axonics (NASDAQ:AXNX) 株価情報

Axonics

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Axonics Modulation Tech

Axonics Inc

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) reported quarterly earnings of $1.61 per share which beat the analyst consensus estimate of $1.59 by 1.26 percent. This is a 20.15 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $159.30 million which beat the analyst consensus estimate of $155.57 million by 2.40 percent. This is a 16.53 percent increase over sales of $136.71 million the same period last year.

Earnings

Earnings Beats

News

COLL

Collegium Pharmaceutical Q3 Adj $1.61 Beats $1.59 Estimate, Sales $159.30M Beat $155.57M Estimate

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

Guidance

CUTR

Cutera Affirms FY2024 Sales Guidance to $140.00M-145.00M  VS Est.141.53M

Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) lowers FY2024 sales outlook from $450.00 million-470.00 million to $440.00 million-455.00 million.

PRCH

Porch Group Lowers FY2024 Sales Guidance from $450.00M-470.00M to $440.00M-455.00M

BILL

BILL Holding Sees FY25 Adj. EPS $1.65-$1.83 Vs $1.55 Est.; $1.439B-$1.464B Vs $1.437B

Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) reported $354.41 thousand in sales this quarter. This is a 115.91 percent increase over sales of $164.15 thousand the same period last year.

REFR

Research Frontiers Q3 Sales $354.41K Up From $164.15K YoY

BILL Holding Sees Q2 Adj. EPS $0.44-$0.48; Revenue $355.5M-$360.5M

ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.14 by 142.86 percent. The company reported quarterly sales of $285.25 million which missed the analyst consensus estimate of $316.34 million by 9.83 percent. This is a 17.67 percent increase over sales of $242.42 million the same period last year.

Earnings Misses

ProAssurance Q3 2024 Adj EPS $0.34 Beats $0.14 Estimate, Sales $285.25M Miss $316.34M Estimate

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) affirms FY2024 sales outlook from $410.00 million-425.00 million to $410.00 million-425.00 million.

BRLT

Brilliant Earth Group Affirms FY2024 Sales Guidance from $410.00M-425.00M to $410.00M-425.00M

Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) reported quarterly earnings of $10.21 per share which beat the analyst consensus estimate of $10.01 by 2 percent. The company reported quarterly sales of $954.53 million which beat the analyst consensus estimate of $944.74 million by 1.04 percent. This is a 1.28 percent increase over sales of $942.46 million the same period last year.

Mettler-Toledo Intl Q3 2024 Adj EPS $10.21 Beats $10.01 Estimate, Sales $954.53M Beat $944.74M Estimate

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) affirms FY2024 Adj EPS guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 analyst estimate. Narrows FY2024 sales outlook from $338.00 million-353.00 million to $346.00 million-350.00 million vs $344.10 million estimate.

CCSI

Consensus Cloud Solns Affirms FY2024 Adj EPS Guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 Est; Narrows FY2024 Sales Guidance from $338.00M-353.00M to $346.00M-350.00M vs $344.10M Est

Outlook2
For the fourth quarter ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $370 million to $380 million (32-35% growth compared to Q4 2023)</li>
<li>Adjusted EBITDA in the range of $90 million to $100 million</li>
</ul>
For the full year ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $1,395 million to $1,405 million (32-33% growth compared to 2023, up from 27-29% growth)</li>
<li>Adjusted EBITDA in the range of $352 million to $362 million (up from $285 million to $305 million)</li>
</ul>
The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding "Forward-looking Statements" in this press release.

TOST

Toast Sees Q4 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $370M-$380M; FY24 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $1.395B-$1.405B

Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent.

ALLO

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $286.87 million which beat the analyst consensus estimate of $282.56 million by 1.52 percent. This is a 4.16 percent increase over sales of $275.40 million the same period last year.

GTBIF

Green Thumb Industries Q3 EPS $0.04 Misses $0.06 Estimate, Sales $286.87M Beat $282.56M Estimate

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) lowers FY2024 Adj EPS guidance from $5.13-5.20 to $1.15-1.19 vs $1.29 analyst estimate. Lowers FY2024 sales outlook from $944.00 million-950.00 million to $939.00 million-943.00 million vs $946.02 million estimate.

NVEE

NV5 Global provides FY2024 guidance: Gross revenues $939M-$943M (est. 946.02M); GAAP EPS $0.48-$0.54 (est. 0.67); Adj. EPS $1.15-$1.19 (adjusted for 4-1 stock split) vs (est. 1.29)

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) is looking for Q4 Adj EPS of $1.14-1.24 vs $1.21 analyst estimate. sees sales of $83.000 million-87.000 million vs $83.26 million estimate.

Consensus Cloud Solns Sees Q4 Adj EPS $1.14-1.24 vs $1.21 Est; Sees Sales $83.000M-87.000M vs $83.26M Est

SENS

Senseonics Sees FY24 Revenue $22M Vs $22.182M Est.

DXC Technology Sees Q3 2025 Revenue $3.2B-$3.3B Vs $3.2B Est.; Sees Adj EPS $0.75-$0.80 Vs $0.72 Est.

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $1.965 million which missed the analyst consensus estimate of $5.420 million by 63.74 percent. This is a 56.60 percent decrease over sales of $4.528 million the same period last year.

GEVO

Gevo Q3 2024 GAAP EPS $(0.09) Misses $(0.07) Estimate, Sales $1.965M Miss $5.420M Estimate

SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.00 million in sales this quarter. This is a 8.28 percent increase over sales of $9.23 million the same period last year.

SIGA

SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY

PODD

Insulet Raises FY24 Revenue Growth To Range Of 20% - 21% (Previously 16% -19%)

Top Merger Stocks Held By Fund Managers, Mid-Q3 2024

Tracking George Soros's 13F Portfolio - Q2 2024 Update

Axonics gains after win in trial in patent dispute with Medtronic

Piper Sandler analyst Adam Maeder maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target...

Piper Sandler Keeps Their Hold Rating on Axonics Modulation Technologies (AXNX)

Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more

Axonics gets regulatory nod for fourth-generation rechargeable SNM system in Australia

Axonics gains after Boston Scientific says it will end use of Coaptite on Nov. 1

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) on October 8 and set a...

Axonics Modulation Technologies (AXNX) Receives a Hold from RBC Capital

Catalyst Watch: Earnings blitz, Fed speakers, and notable healthcare conferences

Axonics' Market Growth Strengthens Boston Scientific's Future

AAPL

ALTM

AMED

ANRO

ANSS

ARMK

ASAN

AXNX

AZNCF

BABA

BABAF

BATL

BIOX

BKNG

BLCO

BOOM

BYON

CACI

CALM

CAMRF

CBOE

CFLT

COST

CPRI

CTLT

DENN

ETON

FFIE

FLUT

GOOG

GOOGL

INFN

JDCMF

JNPR

LBRDA

LBRDB

LBRDK

LBRDP

LOGI

LSXMA

LSXMB

LSXMK

MEDP

MMSI

MNDY

NONOF

OKTA

OMIC

PLTK

PYTCY

QCOM

RIVN

RVNC

SATS

SMAR

SRCL

SRDX

STZHF

TEAM

TMUS

TSLA

UBER

VVPR

WHLR

Press Releases

Axonics Provides Update on Inter Partes Review Proceedings

Axonics Stockholders Approve Merger Agreement with Boston Scientific

Boston Scientific Announces Results for First Quarter 2024

Axonics Reports First Quarter 2024 Financial Results

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

Axonics Reports Second Quarter 2024 Financial Results

Axonics Prevails in Patent Infringement Lawsuit with Medtronic

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

Comments

Axonics

ニュース

最新ニュース Axonics (NASDAQ:AXNX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル